Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Bone. 2017 Dec 28;108:79–88. doi: 10.1016/j.bone.2017.12.025

Fig. 4.

Fig. 4

Prevalence of MRONJ lesions (study 2). (A) Prevalence of rats with gross MRONJ by ZOL dose and duration. Prevalence increased with increasing ZOL dose (P < 0.001), but not increasing duration of ZOL exposure (P=0.297). Gross MRONJ lesions were not found in ZOL0 or osteoporosis (OP) ZOL (8 µg/kg) groups. (B) Prevalence of rats with histopathologic MRONJ by time and ZOL dose in quadrants with GQG ≥ 1. Prevalence of histopathologic MRONJ increased with increasing ZOL dose (P < 0.001) but not increasing duration of ZOL exposure (P = 0.326). Histopathologic MRONJ was never found in ZOL0 rats; two cases were present in the OP ZOL (8 µg/kg) group at 30 weeks.